Healthmap Solutions, a kidney disease-focused national population health management company and a portfolio firm of WindRose Health Investors, has secured $100 million for its expansion. The funding will support new business ventures and strengthen its balance sheet for capitated arrangements. Over 160,000 individuals are served by Healthmap’s contracted health plan customers. The investment was led by WindRose, with StepStone Group and other new and existing investors joining. Healthmap’s innovative approach to kidney disease management has garnered market enthusiasm, aiming to enhance care while minimizing costs.
WindRose Health Investors, LLC (“WindRose”), a leading healthcare-focused private equity firm, announced that its portfolio company, Healthmap Solutions, Inc. (“Healthmap”), has raised $100 million to support the ongoing expansion of its business. Healthmap is a national population health management company focused on kidney disease. The company has grown rapidly and is currently contracted with its health plan customers to serve over 160,000 individuals.
The funding will provide the company with the resources to implement newly awarded business and the balance sheet strength to support the growing portion of HealthMap’s covered lives that are contracted under capitated arrangements. Today, Healthmap is contracted to manage over $3 billion in healthcare spend through risk-based arrangements with a number of the country’s leading health plans and at-risk providers. WindRose financed the transaction, which included commitments from WindRose’s sixth fund as well as a new WindRose vehicle capitalized and led by StepStone Group (“StepStone”) and joined by other new and existing investors.
“We are thrilled to build on our partnership with Healthmap as they expand their business and fulfill their mission of improving care and lowering costs for polychronic patients,” said Oliver T. Moses, WindRose Managing Partner.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Adam Johnston, Partner at StepStone said, “We are excited to support a high-quality asset in Healthmap that can make a material positive impact on patient outcomes. We believe WindRose is the ideal partner to continue generating value for all stakeholders involved.”
Eric Reimer, Healthmap’s Chief Executive Officer said, “We are grateful for the ongoing support of our investor group and excited to have ample resources to maintain our rapid growth. We believe that Healthmap has built a differentiated approach to managing chronic kidney disease. It is rewarding to see the market’s enthusiasm for our program and the positive impact we are having on patients’ lives.”
Evercore served as financial advisor on the transaction and Weil, Gotshal & Manges LLP served as legal advisor.
Source: BioSpace